Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)

The Microbial-based Cancer Imaging and Therapy - Bugs as Drugs grant (R01 Clinical Trial Not Allowed) invites applications that aim to explore the role of microorganisms, like bacteria, archaebacteria, bacteriophages and non-oncolytic viruses in studying cancer. The research focus should be on their potential use in cancer diagnostics, imaging, and therapeutics. The grant encourages the assessment of complex interplays between microorganisms, tumors, and the immune system. Researchers may choose to investigate the use of microorganisms in various capacities, such as delivery vehicles for treatment, as anti-tumor agents or as triggers of anti-tumor immunity. These studies could offer valuable adjunct or alternative to existing cancer treatment and diagnostic methods.

This funding supports fundamental mechanistic investigations and preclinical trials in cell cultures and animal models. Researchers should equally pay attention to microbe and tumor aspects of the microbial-tumor interactions that are crucial for microbial-based cancer therapy. This includes therapies for oral cancer, tumor imaging, detection, or diagnosis. The grant offer is a part of a larger initiative by the NCI (National Cancer Institute) to propel research into microbial-based cancer treatment. For more information, you can visit the OCCAM link provided.